Search companies

Live

Tuesday, 17 November 2026 · 581 Summaries Today

S&P/ASX 200 · 8,883.20 (-1.79%)

Miro Sciences Clears TGA Inspection Milestone Ahead Of Planned Crohn’s Trial

MSX: $0.041 +0.00% · MC: $16M

Miro Sciences says the TGA has completed its inspection of manufacturing partner Q-Gen, a step towards supplying StemSmart for a planned Phase 2 trial in treatment-resistant Crohn’s disease, subject to regulatory approvals. The company is targeting trial initiation by the end of 2026, following positive FDA feedback and the appointment of a clinical research organisation in October.

Source announcements: 2026-11-12 09:03 to 2026-11-12 09:03 Sydney time
Story updated 2026-11-12 09:07 Sydney time
SourcesManufacturing Milestone Achieved - TGA Inspection Completed
Comments